Wockhardt will launch its new antibiotic Zaynich in the United States on its own, turning down the licensing deals that most Indian drugmakers chase when they carry an innovative product into a developed market. Founder and chairman Habil Khorakiwala told Moneycontrol the company wants to keep the value of the drug rather than hand it to a global partner, and use the launch to build something it can reuse.
The choice is a wager, not a formality. Licensing brings quick, low-risk cash, while going solo in the world’s toughest antibiotics market means building a sales operation from scratch and betting it pays off across a whole pipeline. The history of that market shows why most companies take the cheque.
Why Wockhardt Is Skipping the Licensing Cheque
For decades the standard play for an Indian company with a genuinely new molecule has been to partner out the developed-market rights. A multinational fronts the sales force, absorbs the launch risk, and the innovator collects milestones and royalties. Khorakiwala looked at that route for Zaynich and walked away from it without a global partner attached.
His reasoning is about leverage over the next ten years, not this one drug. Build the commercial team once, he argues, and every future launch rides on infrastructure that is already paid for.
We had both the options available. We thought this is a better option because tomorrow I introduce another drug, I don’t need, my organisation is already there.
That was Khorakiwala, speaking in an interview with Moneycontrol. The company has already begun hiring, putting senior staff in place across medical affairs, sales, marketing and market access while outsourcing operational work such as data management. The leadership sits in-house, he said, and the back-office people can be rented.
The Resistance Math Behind the Wager
The demand case for a drug like this is grim and growing. Bacteria that shrug off existing antibiotics are spreading faster than the industry is replacing the medicines, and the gap is widest in exactly the Gram-negative infections Zaynich targets.
- 39 million deaths are forecast to be directly attributable to bacterial antimicrobial resistance (AMR, infections that no longer respond to standard drugs) between 2025 and 2050, according to the Lancet’s global forecast on antimicrobial-resistance deaths.
- 1.14 million annual deaths in 2021 are projected to climb to 1.91 million a year by 2050, a rise of about 68 percent.
- 11.1 million of those deaths could be averted by 2050 if a stronger Gram-negative drug pipeline reaches patients, the same study estimates.
- Three deaths a minute is the pace the researchers attach to that 25-year toll.
That is the backdrop Wockhardt is selling into. The clinical need is not in doubt. Whether hospitals will pay for the answer is the part that has bankrupted better-funded companies.
What Zaynich Brings to the Bedside
Zaynich is an intravenous combination of cefepime, a fourth-generation cephalosporin, and zidebactam, a new compound that Wockhardt classifies as a beta-lactam enhancer rather than the inhibitor that older resistance drugs rely on. The US Food and Drug Administration (FDA) cleared it on June 1, 2026, for adults with complicated urinary tract infection (cUTI, a kidney or bladder infection that has spread or resisted first-line treatment), including pyelonephritis.
| Region | Status | Launch timeline |
|---|---|---|
| United States | FDA approved | 6 to 8 months out |
| India | Approved | Slightly ahead of the US |
| Europe | Filed | Approval expected later this year, launch roughly a year behind |
The Enhancer Mechanism
The two molecules bind several penicillin-binding proteins at once, the structures bacteria use to build their cell walls. Khorakiwala says that approach lets the drug overcome resistance machinery that defeats conventional treatments, including the metallo-beta-lactamase producers behind some of the hardest cases. On the wards that means activity against Pseudomonas, Acinetobacter, Klebsiella and Stenotrophomonas, the pathogens that fill intensive-care units with infections clinicians have run out of options for.
What the Phase 3 Data Showed
In the pivotal ENHANCE-1 study, Zaynich posted a combined clinical-cure and microbiologic-response rate of 89.0% versus 68.4% for meropenem, a treatment gap of 20.6 percentage points. The agency granted it Qualified Infectious Disease Product (QIDP, a status that adds market exclusivity for new antibiotics) designation along with Fast Track and Priority Review. Wockhardt calls it the first new chemical entity fully developed and commercialised by an Indian company to win FDA approval, a claim laid out in the company’s Phase 3 ENHANCE-1 trial disclosure.
The Graveyard of FDA-Approved Antibiotics
Approval is the cheap part. The expensive part is getting a hospital to choose a costly new antibiotic over a generic, and that is where solo launches go to die. American hospitals are reimbursed for antibiotics inside a bundled payment, so a pricier drug eats into the margin rather than adding to it, and stewardship rules deliberately hold new agents in reserve. Low volumes plus thin economics have buried a string of companies that did exactly what Wockhardt is about to do.
- Achaogen won FDA approval for plazomicin in 2018, booked roughly $800,000 in sales by year-end, and filed for Chapter 11 bankruptcy on April 15, 2019.
- Its assets fetched about $16 million at auction, with Cipla buying the worldwide rights to the drug, sold as ZEMDRI, for $4.8 million upfront.
- Melinta Therapeutics, carrying multiple approved antibiotics, filed for bankruptcy protection in December 2019.
The pattern is structural, not a run of bad management. A financial post-mortem of plazomicin’s commercial failure traces the collapse to a market that rewards volume the moment stewardship is designed to suppress it. The bankruptcy paperwork tells the same story; Achaogen reported a formulary-approval rate near 98 percent in its Chapter 11 auction filings and still ran out of cash. Getting on the shelf was never the problem. Getting prescribed was.
The Price Tag and the Hockey Stick
Wockhardt’s answer to thin economics is to price Zaynich where the newest antibiotics already sit and to lean on a much larger global ceiling than any single failed launch reached. Khorakiwala expects a course to cost in line with other advanced agents in the US, and far less at home.
| Market | Price per course | Rationale |
|---|---|---|
| United States | $10,000 to $15,000 (7 to 10 days) | In step with advanced antibiotics |
| India | About 75 to 80 percent lower | Priced for local affordability |
The ceiling is the number that makes the solo gamble worth it. Khorakiwala pegs Zaynich’s global peak sales at $1.5 billion to $2 billion a year, against a benchmark in which the entire pool of newer antibiotics on the market collectively generates roughly $1 billion annually. In other words, he expects one drug to do what the existing field does combined.
The timing is back-loaded. Revenue starts in fiscal 2028, he said, with the real ramp the following year. “You have to give me 12 to 15 months. FY28 onwards revenue will start, FY29 would be zoom year. It will be like hockey stick,” Khorakiwala told Moneycontrol. India rolls out slightly earlier, and Europe trails by about a year once pricing and country approvals clear.
Building a Sales Engine for the Pipeline
The deeper logic is that the launch team is the asset, not just the launch. Khorakiwala says the same commercial structure built for one antibiotic can carry the next three, four or five products out of the pipeline with little added cost, which is why a marketing organisation he estimates at 50 to 100 people looks affordable to him spread across future drugs.
He also argues a novel antibiotic sells differently from a consumer brand, through scientific and medical engagement rather than conventional promotion, which keeps the field force lean. That sits inside a broader reset for a company that has spent years under financial strain while pouring money into research, and that now wants innovation and biologicals to drive its revenue within five years.
If the fiscal 2029 scale-up lands the way Khorakiwala predicts, the team being hired now becomes an asset every later drug inherits for free. If American hospitals treat Zaynich the way they treated the novel antibiotics before it, Wockhardt will have bought an expensive lesson the rest of the industry already paid for.
Disclaimer: This article is for informational purposes only and is not investment advice. It discusses a listed pharmaceutical company’s commercial strategy and forward-looking revenue projections, which carry execution, regulatory and market risk. Readers should consult a qualified financial professional before making investment decisions. Figures are accurate as of publication.
